Cipla was officially opened on September 22, 1937 when the first products were ready for the market. The Sunday Standard wrote: "The birth of Cipla which was launched into theworld by Dr. K.A. Hamied will be a red letter day in the annals of Bombay Industries.The first city in India can now boast of a concern, which will supersede all existing firmsin the magnitude of its operations. India has lagged behind in the march of science butshe is now awakening from her lethargy. The new company has mapped out an ambitious programme and with intelligent direction and skillful production bids fair to establish agreat reputation in the East. "
Cipla occupies the third position in the domestic formulations market and commands a marketshare of 4.74 per cent. Cipla currently markets over 350 products and is the market leader in thegeneric segment consisting of more than 100 products. The company has strong presence in anti-asthmatic, antibiotics, cardiovascular, anti-AIDS and anticancer areas. Cipla was the first one toenter into the competitive generics business and has occupied the leadership position in thissegment.Cipla is the market leader in anti asthmatic inhaler segment with over 70 per cent market share.This segment is growing rapidly mainly due to increase in pollution leading to a spurt in thenumber of asthma cases in patients. One of its major products, Asthalin inhaler has annual salesof more than Rs 30 crore. The company offers full range of inhalers, rotahalers and spacers thathave gained excellent acceptance among the asthma patients. The company has introduced CFC-free, environment-friendly Budecort inhalers for the first time in India. The CFC- free productshave a huge export potential .The inhaler therapy is preferred to tablets since the dose required isabout 1/ 10 of the oral dose. Moreover, the drug directly goes to the lung and gives instantaneousrelief to the patient. Cipla will be maintaining a leadership position due to the entire range of inhalers and with the advantage of economies of scale.Cipla has presence in niche segments such as cardiovascular, anti-AIDS, and anticancer. Thecompany has several products in each of these segments that will help it maintain a steadygrowth in the long run. Cipla is building a strong presence in the anti-AIDS segment and isoffering the entire range of products. The company has reduced the prices of anti-AIDS drug fivetimes in the domestic market through technological advancements. The company's recent offer to